At BIO 2026, EirGenix presented its comprehensive HER2-positive breast cancer biosimilar portfolio and highlighted its integrated one-stop contract development and manufacturing organization (CDMO) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results